Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, John F. Seymour, Matthew S. Davids et al.|New England Journal of Medicine|2015Cited by 1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Ahmed Hamed Salem et al.|Journal of Clinical Oncology|2017Cited by 752
Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al.|Journal of Clinical Oncology|2014Cited by 91
A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin LymphomaJohn F. Gerecitano, Matthew S. Davids, Andrew W. Roberts et al.|Blood|2015Cited by 74
Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)Matthew S. Davids, Andrew W. Roberts, John M. Pagel et al.|Blood|2013Cited by 69